These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 19845817)
1. Metabolic profiling reveals key metabolic features of renal cell carcinoma. Catchpole G; Platzer A; Weikert C; Kempkensteffen C; Johannsen M; Krause H; Jung K; Miller K; Willmitzer L; Selbig J; Weikert S J Cell Mol Med; 2011 Jan; 15(1):109-18. PubMed ID: 19845817 [TBL] [Abstract][Full Text] [Related]
2. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma. Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065 [TBL] [Abstract][Full Text] [Related]
3. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients. Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969 [TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593 [TBL] [Abstract][Full Text] [Related]
7. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes. Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664 [TBL] [Abstract][Full Text] [Related]
8. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma. Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216 [TBL] [Abstract][Full Text] [Related]
9. Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis. Xu X; Fang Y; Wang Q; Zhai S; Liu W; Liu W; Wang R; Deng Q; Zhang J; Gu J; Huang Y; Liang D; Yang S; Chen Y; Zhang J; Xue W; Zheng J; Wang Y; Qian K; Zhai W Adv Sci (Weinh); 2024 Sep; 11(34):e2401919. PubMed ID: 38976567 [TBL] [Abstract][Full Text] [Related]
10. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma. Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842 [TBL] [Abstract][Full Text] [Related]
11. Eight proteins play critical roles in RCC with bone metastasis via mitochondrial dysfunction. Wang J; Zhao X; Qi J; Yang C; Cheng H; Ren Y; Huang L Clin Exp Metastasis; 2015 Aug; 32(6):605-22. PubMed ID: 26115722 [TBL] [Abstract][Full Text] [Related]
12. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452 [TBL] [Abstract][Full Text] [Related]
13. Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features. Tariq N; Mamoon N; Haroon A; Ali Z; Ahmad IN J Ayub Med Coll Abbottabad; 2018; 30(3):325-332. PubMed ID: 30465359 [TBL] [Abstract][Full Text] [Related]
14. High Membranous Expression of Fatty Acid Transport Protein 4 Is Associated with Tumorigenesis and Tumor Progression in Clear Cell Renal Cell Carcinoma. Kim YS; Jung J; Jeong H; Lee JH; Oh HE; Lee ES; Choi JW Dis Markers; 2019; 2019():5702026. PubMed ID: 31089396 [TBL] [Abstract][Full Text] [Related]
15. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263 [TBL] [Abstract][Full Text] [Related]
16. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851 [TBL] [Abstract][Full Text] [Related]
17. Down-Regulation of Circular RNA_000926 Attenuates Renal Cell Carcinoma Progression through miRNA-411-Dependent CDH2 Inhibition. Zhang D; Yang XJ; Luo QD; Fu DL; Li ZL; Zhang P; Chong T Am J Pathol; 2019 Dec; 189(12):2469-2486. PubMed ID: 31476285 [TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia. Karim S; Al-Maghrabi JA; Farsi HM; Al-Sayyad AJ; Schulten HJ; Buhmeida A; Mirza Z; Al-Boogmi AA; Ashgan FT; Shabaad MM; NourEldin HF; Al-Ghamdi KB; Abuzenadah A; Chaudhary AG; Al-Qahtani MH BMC Cancer; 2016 Sep; 16(Suppl 2):741. PubMed ID: 27766950 [TBL] [Abstract][Full Text] [Related]
19. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer. Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628 [TBL] [Abstract][Full Text] [Related]
20. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. Horstmann M; Merseburger AS; von der Heyde E; Serth J; Wegener G; Mengel M; Feil G; Hennenlotter J; Nagele U; Anastasiadis A; Bokemeyer C; Stenzl A; Kuczyk M J Cancer Res Clin Oncol; 2005 Nov; 131(11):715-22. PubMed ID: 16080018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]